Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: Increased toxicity without improvement in progression-free survival

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 741-748

  Shea, Thomas C ^a,b   Beaven, Anne W ^c   Moore, Dominic ^b,d   Serody, Jonathan ^a,b   Gabriel, Don ^a,b   Chao, Nelson ^c   Gockerman, Jon ^c   Garcia, Reynaldo A ^b   Rizzieri, David ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d IL   (United States)

Author keywords

Chemotherapeutic approaches; Lymphoma and Hodgkin disease; Pharmacotherapeutics

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; RITUXIMAB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 68449102373     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902853136     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
3. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediateand advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198-9207.
4. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 2005;16:1359-1365.
5. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-2071.
6. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. Ann Oncol 1999;10:13-19.
7. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy- sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
8. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-3688.
9. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-3785.
10. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006;17(Suppl. 4):iV25-iv30.
11. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)- based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14(Suppl. 1):i5-i10.
12. Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma - the Nordic lymphoma group experience. Eur J Haematol 2004;73:179-182.
13. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977;61: 1307-1317.
14. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
15. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
16. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, et al. Efficacy, toxicity, and applicability of highdose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 1997;15:2312-2321.
17. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995;273:542-547.
18. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
19. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk nodepositive breast cancer: A phase II study. J Clin Oncol 1999;17:1118.
20. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003;21:1431-1439.
21. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259.
22. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non- Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. Groupe d'etude des lymphomes de l'adulte. J Clin Oncol 1997;15:1131-1137.
23. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups. Br J Haematol 1996;92:880-889.
24. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the autologous blood and marrow transplant registry. J Clin Oncol 2001;19:406-413.
25. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry. J Clin Oncol 1999;17:534-545.
26. Simon R, Norton L. The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006;3:406-407.
27. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.